| Phase 21 trial |
|
Phase 2
|
NCT00805389 |
Dec 2008 → Sep 2010 |
hepatitis B virus infection |
GlaxoSmithKline |
Completed
|
No outcome recorded
|
| Phase 41 trial |
|
Phase 4
|
NCT03410953 |
Apr 2018 → Oct 2019 |
acute hepatitis B virus infection |
Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León |
Completed
|
No outcome recorded
|
| Phase not applicable3 trials |
| — |
NCT03459521 |
Sep 2017 → Aug 2021 |
hepatitis B virus infection |
Corporacion Parc Tauli |
Completed
|
No outcome recorded
|
| — |
NCT04515368 |
Jun 2016 → Sep 2020 |
— |
Imperial College London |
Completed
|
No outcome recorded
|
| — |
NCT02032160 |
May 2014 → Feb 2016 |
hepatitis B virus infection |
University of Surrey |
Completed
|
No outcome recorded
|
| Comparator or background therapy5 trials |
|
Phase 2/3
|
NCT02434848 Comparator |
Jul 2015 → Jun 2022 |
HIV infectious disease, hepatitis B virus infection |
Sheffield Teaching Hospitals NHS Foundation Trust |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT01195246 Comparator |
Dec 2010 → Feb 2012 |
end stage renal failure |
Dynavax Technologies Corporation |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT00445185 Comparator |
Mar 2007 → Jul 2009 |
hepatitis B virus infection |
Henogen |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT00291941 Comparator |
Feb 2006 → Mar 2007 |
hepatitis B virus infection |
Henogen |
Completed
|
No outcome recorded
|
| — |
NCT02368327 Comparator |
Feb → Jul 2015 |
— |
University of Surrey |
Completed
|
No outcome recorded
|